Staphylococcus xylosus bacteriophage with high fermentation rate and excellent temperature resistance and application of staphylococcus xylosus bacteriophage
By developing the phage GRNSXP16 with high fermentation rate and excellent temperature resistance, the infection control difficulties caused by the multiple resistance of Staphylococcus xylose is solved, and efficient infection prevention and control and temperature stability are achieved, which reduces health and economy cost.
Patent Information
- Application Number
- CN202411165071.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-12-03
AI Technical Summary
Multi-drug resistance of Staphylococcus xylose leads to difficulty in controlling infections, and the prior art is difficult to effectively prevent and treat infections caused by this strain, and antibiotic resistance brings high economic and health costs.
A high fermentation rate and excellent temperature resistance of Staphylococcus xylose phage GRNSXP16 was developed to prepare drugs, antibacterial agents and feed additives for the treatment or prevention of Staphylococcus xylose infection, through the lysis of 100 strains of Staphylococcus xylose The rate is as high as 95%, and the stability is maintained under different temperature conditions.
The phage of Staphylococcus xylose GRNSXP16 has efficient cleavage ability to Staphylococcus xylose, high fermentation titer and temperature resistant, can effectively prevent and treat infections, reduce health risks, and show good temperature stability during industrial fermentation.
Smart Images

Figure BDA0005007618430000051 
Figure BDA0005007618430000061 
Figure HDA0005007618440000011
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of microorganisms, in particular to a Staphylococcus xylosus phage with high fermentation rate and excellent temperature resistance and application thereof. Background Art
[0002] Staphylococcus xylosus is a Gram-positive bacterium with biological characteristics such as facultative anaerobic, chemoheterotrophic, catalase-positive, and oxidase-negative. In the early days, Staphylococcus xylosus was used as a fermentation bacterium in the wax products industry. However, in recent years, scientists have found that its drug-resistant strains have been increasingly detected, and its presence has become more and more common in clinical practice. Staphylococcus xylosus can cause suppurative infections in patients, and in aquaculture, it can cause abdominal effusions, white livers and gills in fish, and other characteristics.
[0003] The World Health Organization has declared antimicrobial resistance one of the top ten global public health threats facing humanity. It has been reported that multidrug-resistant Staphylococcus xylosus strains that are resistant to penicillin, oxacillin, erythromycin, ciprofloxacin, and cotrimoxazole have been found, and such strains have developed into coagulase-negative Staphylococci (CNS) that are more difficult to control; antimicrobial resistance brings huge economic costs. In addition to death and disability, long-term illness leads to longer hospital stays, the need for more expensive drugs, and a heavy economic burden on those affected.
[0004] The neglect of the pathogenicity of Staphylococcus xylosus in the early days has led to the current multi-drug resistance of Staphylococcus xylosus. The use of antibiotics to treat it requires correct drug sensitivity test analysis to guide the use of drugs. Today, antibiotic resistance will certainly become more serious. The state encourages the research and development of safe, green, and targeted alternative antibiotic products. Phages are very green, healthy, residue-free, sustainable, and highly targeted bacterial viruses. Based on this, the present invention provides a Staphylococcus xylosus phage with high fermentation rate and excellent temperature resistance and its application. Summary of the invention
[0005] In order to prevent the infection problem caused by Staphylococcus xylosus and reduce the health risk caused by the problem, one of the purposes of the present invention is to provide a bacteriophage GRNSXP16 against Staphylococcus xylosus, and the deposit number of the bacteriophage is CCTCC NO: M20241532.
[0007] Another object of the present invention is to provide an application of Staphylococcus xylosus bacteriophage GRNSXP16.
[0008] In order to achieve the above object, the present invention adopts the following technical measures:
[0009] Obtaining a phage with high fermentation rate and excellent temperature resistance against Staphylococcus xylosus:
[0010] The applicant isolated a Staphylococcus xylosus phage GRNSXP16 from a water body in Wuhan City, Hubei Province. The phage was deposited in the China Center for Type Culture Collection on July 10, 2024, and the classification name was: Staphylococcusxylosus phage GRNSXP16. The storage address is: Wuhan University, Wuhan, China; the storage number is CCTCC NO: M20241532.
[0011] The protection scope of the present invention also includes:
[0012] A compound comprises a Staphylococcus xylosus phage with a deposit number of CCTCC NO: M20241532.
[0013] Application of the bacteriophage or compound in the preparation of medicine for treating or preventing Staphylococcus xylosus infection.
[0014] Application of the bacteriophage or compound in the preparation of non-therapeutic Staphylococcus xylosus antibacterial agent.
[0015] In the above application, the Staphylococcus xylosus is preferably thermostable Staphylococcus xylosus.
[0016] In the above application, preferably, the high temperature range that the thermostable Staphylococcus xylosus can tolerate is ≤45°C;
[0017] Application of the bacteriophage or compound in the preparation of feed additives antagonizing Staphylococcus xylosus.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] 1. The lysis rate of xylosus Staphylococcus phage GRNSXP16 against 100 strains of xylosus Staphylococcus is as high as 95%, which can effectively prevent and treat the infection of xylosus Staphylococcus.
[0020] 2. The xylose Staphylococcus phage GRNSXP16 has an ultra-high fermentation rate and a high fermentation titer. Under the conditions of 35°C and 250rpm, the fermentation titer can reach 8.3*10 12 pfu / mL; In the industrial fermentation process, the fermentation titer can reach 8.5×10 12 PFU / mL.
[0021] 3. The xylose Staphylococcus aureus phage GRNSXP31 has good temperature tolerance, and the xylose Staphylococcus aureus phage GRNSXP16 has a longer survival time at temperatures of 45°C and below, and can be preserved at the same order of magnitude for 120 hours and can be preserved for 32 weeks; under conditions of 4°C to 37°C, after the phage is preserved for 48 weeks, there is little difference in potency before and after. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 This is a plaque of Staphylococcus xylosus phage GRNSXP16.
[0023] Figure 2 The titer of Staphylococcus xylosus phage GRNSXP16 under different infection multiplicity conditions.
[0024] Figure 3 These are the test results of the stability of Staphylococcus xylosus phage GRNSXP16 at different temperatures.
[0025] Figure 4 Schematic diagram of the fermentation dynamics of Staphylococcus xylosus phage GRNSXP16. DETAILED DESCRIPTION
[0026] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further described below in conjunction with specific implementation methods. The technical solutions described in the present invention, unless otherwise specified, are conventional solutions in the field, and the reagents or materials, unless otherwise specified, are all derived from commercial channels.
[0027] Embodiment 1:
[0028] Isolation and Purification of Staphylococcus xylosus Phage GRNSXP16
[0029] Thirty 50 mL water samples were collected from a water body in Wuhan, Hubei Province, and centrifuged at 6000 rpm for 10 min. The supernatant was sterilized with a 0.22 μm filter. 20 mL of the filtrate was mixed with 1 mL of Staphylococcus xylosus (concentration of about 5 × 10 8 CFU / mL) were mixed evenly and cultured overnight in a shaker at 37°C at 200 rpm. The fermentation broth was centrifuged at 6000 rpm for 10 min, the supernatant was sterilized with a 0.22 μm filter, and 100 μL of the filtrate was mixed with 300 μL of Staphylococcus xylosus (concentration was about 1×10 8CFU / mL) and mix well, add TSB semi-solid (containing 0.65% agar), gently invert and pour evenly on the TSA bottom plate, and after solidification, place the culture dish in a 37°C incubator for overnight culture. Pick up the transparent and bright plaque spots, shake and desorb in 1mL SM liquid, and sterilize through a 0.22μm microporous filter to obtain the phage filtrate, inoculate it in 5mL TSB liquid culture medium, add 500μL of the corresponding host xylose Staphylococcus aureus liquid and mix well, shake and culture at 200rpm overnight at 37°C, centrifuge at 6000rpm for 10min, take the supernatant and sterilize through a 0.22μm microporous filter to obtain the phage filtrate, and observe the plaque morphology by double-layer plate method. After repeating the operation 3-5 times, plaques of uniform shape and size can be obtained.
[0030] A Staphylococcus xylosus phage GRNSXP16 was isolated from the water sample. Figure 1 As shown, the plaques formed by it and the host bacteria are transparent, round, and 0.5 mm in diameter. The phage has been deposited in the China Center for Type Culture Collection on July 10, 2024, with the classification name: Staphylococcus xylosus phage GRNSXP16, address: Wuhan University, Wuhan, China, and the deposit number: CCTCC NO: M 20241532.
[0031] Embodiment 2:
[0032] Determination of the titer of Staphylococcus xylosus phage GRNSXP16 under different infection multiplicity conditions
[0033] The host bacteria of Staphylococcus xylosus phage GRNSXP16, Staphylococcus xylosus WH001, was inoculated into an EP tube with 3 mL of TSB and cultured at 37°C for 5-8 hours to obtain WH001 bacterial solution. The bacterial solution was inoculated into 100 mL of TSB medium at a 1% inoculum. When WH001 grew to the initial logarithmic phase, phage GRNSXP16 was inoculated and the infection was carried out according to different multiplicity of infection (MOI; MOI = number of phages / number of bacteria, see Figure 2 ), each experiment was performed in triplicate. The cells were cultured in a 37°C shaker at 200 rpm for 12 h.
[0034] Results Figure 2 When MOI = 0.01, the fermentation titer reached a maximum of 8.3 × 10 12 PFU / mL.
[0035] Embodiment 3:
[0036] Temperature stability test of Staphylococcus xylosus phage GRNSXP16
[0037] The fermentation broth of Staphylococcus xylosus bacteriophage GRNSXP16 was centrifuged and filtered, and 1 mL was dispensed into 1.5 mL centrifuge tubes (initial titer was 5×10 8 pfu / mL). The centrifuge tubes containing phages were placed in a constant temperature of 4, 25, 37, 45, 55, 65, and 75°C for 0h, 1h, 24h, 48h, 92h, 1w, 2w, 4w, 8w, 12w, and 16w. After the action time, the sample tubes were taken out and immediately placed in an ice bath for cooling. After appropriate dilution, the phage titer was determined by the double-layer plate method. Each point was cultured in duplicate to obtain the average value, and the experiment was repeated 3 times.
[0038] The results are as follows Figure 3 As shown, the xylose Staphylococcus phage GRNSXP16 has a long survival time at temperatures of 45°C and below, and can be stored at the same level within 120 hours. At a high temperature of 45°C, the phage titer gradually decreases with the extension of storage time, and can be effectively preserved at 45°C for up to 32 weeks. Under conditions of 4°C to 37°C, after the phage is stored for 48 weeks, there is little difference in titer before and after. Phage GRNSXP16 has good stability and can be effectively preserved.
[0039] Embodiment 4:
[0040] Host range of bacteriophage GRNSXP16
[0041] The experiment selected 100 strains of xylose Staphylococcus from different sources, including 25 strains from Wuhan, 25 strains from Guangzhou, 20 strains from Shanghai, 20 strains from Beijing, and 10 strains from Qingdao; xylose Staphylococcus were inoculated in 3mL TSB EP tubes, and shaken at 37℃ and 200rpm overnight to obtain xylose Staphylococcus bacterial liquid; prepare a sufficient amount of TSA bottom plate, mix 0.5ml xylose Staphylococcus bacterial liquid with 6mL TSB semi-solid medium (containing 0.65% agar) at about 50℃, and slowly spread it on the TSA bottom plate; after the plate medium solidified to room temperature, take the titer of 1×10 8 5 μL of phage GRNSXP16 with a concentration of PFU / ml was dropped onto the plate, and after air drying, the plate was inverted and placed in a 37°C constant temperature biochemical incubator for about 8 hours, and the results were observed. Each group of experiments was repeated 3 times.
[0042] As shown in Table 1, the xylose Staphylococcus phage GRNSXP16 can lyse 95 of 100 strains of xylose Staphylococcus, with a lysis rate of 95%; the experimental results confirm that this phage has a very outstanding effect in inhibiting Staphylococcus xylose, and has great value for the prevention, control and treatment of Staphylococcus xylose in the future.
[0043] Table 1 Lysis effect of bacteriophage GRNSXP16
[0044]
[0045]
[0046]
[0047] Note: “-” indicates no lysis, and “+” indicates lysis.
[0048] Embodiment 5:
[0049] Fermentation preparation of Staphylococcus xylosus phage GRNSXP16
[0050] A single colony of Staphylococcus xylosus WH001 was picked from the plate, inoculated into 3 mL of TSB medium, and cultured at 37°C and 200 rpm for 8 h to obtain the host bacterial solution. The bacterial suspension was inoculated into 120 mL of TSB medium at a 2% inoculum, and cultured at 37°C and 150 rpm until the early logarithmic phase, and the OD600 value of the bacterial solution was 0.15.
[0051] The industrial fermentation is a 10L fermentation tank, the fermentation system is 6L, the medium used is TSB, the initial pH value is 7.4, the flame method is used to inoculate Staphylococcus xylosus at a 1% inoculation amount, and the phage GRNSXP16 is added to the fermentation system at the optimal infection condition MOI=0.01. Sterile air is introduced during the fermentation process, and 3‰ defoamer is added. The fermentation preparation time is 12h. Since the start of fermentation, 20ml of fermentation liquid is taken from the sampling port in a sterile container at 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h, and centrifuged at 6000rpm for 10min. The supernatant is sterilized through a 0.22μm microporous filter membrane to obtain a filtrate containing phage and its titer is determined. The method is referred to Example 2.
[0052] After the fermentation is completed, the entire mixed solution of phage and host bacteria is taken out from the sampling port and placed in a sterile container, centrifuged at 6000 rpm for 10 min, and the supernatant is filtered through a vacuum pump into a sterile filter device to obtain the phage fermentation solution and stored at 4°C.
[0053] Depend on Figure 4 It can be seen that the titer of Staphylococcus xylosus phage GRNSXP16 reached a maximum of 8.5×10 12 PFU / mL, in the period of 5h to 12h, the titer is stable at 10 12 PFU / mL; The results show that it is feasible to use fermentation method for industrial production of bacteriophages, which provides effective reference data for the preparation of bacteriophage products.
[0054] This embodiment shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It is obvious to those skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and the present invention can be implemented in other specific forms without departing from the spirit or basic features of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the attached claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention. Any figure mark in the claims should not be regarded as limiting the claims involved.
[0055] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.
Claims
1. An isolated Staphylococcus xylosus phage Staphylococcus xylosus phage, the deposit number of the phage is CCTCC NO: M 20241532.
2. A compound comprising a Staphylococcus xylosus phage with a deposit number of CCTCC NO: M20241532.
3. The bacteriophage of claim 1 or the compound of claim 2 in the preparation of a method for treating or preventing Staphylococcus xylosus Staphylococcus xylosus Application of drugs for infection.
4. Use of the bacteriophage according to claim 1 or the compound according to claim 2 in the preparation of a non-therapeutic Staphylococcus xylosus antibacterial agent.
5. The use according to claim 3 or 4, wherein the Staphylococcus xylosus is a thermostable Staphylococcus xylosus.
6. The use according to claim 5, wherein the high temperature range that the thermostable Staphylococcus xylosus can tolerate is ≤45°C.
7. Use of the bacteriophage according to claim 1 or the compound according to claim 2 in the preparation of a feed additive for antagonizing Staphylococcus xylosus.
